Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
An Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy (Hematologic or Nonhematologic)
Malignancy
DRUG: bendamustine
Quantitative determination of the pharmacokinetics (distribution, metabolism, and excretion) of [14C]bendamustine and its metabolites in patients with confirmed, relapsed or refractory malignancy., 168 hours (7 days)
Safety and tolerability of bendamustine will be assessed throughout the study., 8 months
An Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy (Hematologic or Nonhematologic)